This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (74)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Statistics and Research Methods  • Randomized Controlled Trial  • Alert me on articles by topic

Greater Precision But With Greater Uncertainty?

Nick Freemantle, PhD; Melanie Calvert, PhD; John Wood, MSc; Joanne Eastaugh, PhD; Carl Griffin, MSc

JAMA. 2003;289:2554-2559.

Composite outcomes, in which multiple end points are combined, are frequently used as primary outcome measures in randomized trials and are often associated with increased statistical efficiency. However, such measures may prove challenging for the interpretation of results. In this article, we examine the use of composite outcomes in major clinical trials, assess the arguments for and against them, and provide guidance on their application and reporting. To assess incidence and quality of reporting, we systematically reviewed the use of composite end points in clinical trials in Annals of Internal Medicine, BMJ, Circulation, Clinical Infectious Diseases, Journal of the American College of Cardiology, JAMA, Lancet, New England Journal of Medicine, and Stroke from 1997 through 2001 using a sensitive search strategy. We selected for review 167 original reports of randomized trials (with a total of 300 276 patients) that included a composite primary outcome that incorporated all-cause mortality. Sixty-three trials (38%) were neutral both for the primary end point and the mortality component. Sixty trials (36%) reported significant results for the primary outcome measure but not for the mortality component. Only 6 trials (4%) were significant for the mortality component but not for the primary composite outcome, whereas 19 trials (11%) were significant for both. Twenty-two trials (13%) were inadequately reported. Our review suggests that reporting of composite outcomes is generally inadequate, implying that the results apply to the individual components of the composite outcome rather than only to the overall composite. Current guidelines for the undertaking and reporting of clinical trials could be revised to reflect the common use of composite outcomes in clinical trials.

Author Affiliations: Department of Primary Care and General Practice, University of Birmingham, Birmingham, England.

RELATED LETTERS

Use of Composite End Points to Measure Clinical Events
Frank van Leth and Joep M. A. Lange
JAMA. 2003;290(11):1456-1457.
EXTRACT | FULL TEXT  

Effects of Estrogen Plus Progestin on Risk of Dementia—Reply
Sally A. Shumaker, Stephen R. Rapp, Mark A. Espeland, Robert B. Wallace, Susan L. Hendrix, Victor W. Henderson, Margery L. Gass, and Leon Thal
JAMA. 2003;290(13):1707-1708.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Analysis and Reporting of Factorial Trials: A Systematic Review
Finlay A. McAlister, Sharon E. Straus, David L. Sackett, and Douglas G. Altman
JAMA. 2003;289(19):2545-2553.
ABSTRACT | FULL TEXT  

Clinical Trials—Multiple Treatments, Multiple End Points, and Multiple Lessons
Michael S. Lauer and Eric J. Topol
JAMA. 2003;289(19):2575-2577.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Methodologic Issues in Health Informatics Trials: The Complexities of Complex Interventions
Shcherbatykh et al.
J. Am. Med. Inform. Assoc. 2008;15:575-580.
ABSTRACT | FULL TEXT  

Surrogate and Combined End Points in Pulmonary Arterial Hypertension
Ventetuolo et al.
Proc Am Thorac Soc 2008;5:617-622.
ABSTRACT | FULL TEXT  

Randomized Clinical Trials and Observational Studies: Guidelines for Assessing Respective Strengths and Limitations
Hannan
J Am Coll Cardiol Intv 2008;1:211-217.
ABSTRACT | FULL TEXT  

PROactive: time for a critical appraisal
Betteridge et al.
Eur Heart J 2008;29:969-983.
ABSTRACT | FULL TEXT  

Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions Appropriateness of Including Bleeding as a Component of a Quadruple End Point.
Ndrepepa et al.
J Am Coll Cardiol 2008;51:690-697.
ABSTRACT | FULL TEXT  

Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study
Yank et al.
BMJ 2007;335:1202-1205.
ABSTRACT | FULL TEXT  

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)
Sinclair et al.
Lupus 2007;16:972-980.
ABSTRACT  

The Record on Rosiglitazone and the Risk of Myocardial Infarction
Psaty and Furberg
NEJM 2007;357:67-69.
FULL TEXT  

Composite and surrogate outcomes in randomised controlled trials
Freemantle and Calvert
BMJ 2007;334:756-757.
FULL TEXT  

Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials
Ferreira-Gonzalez et al.
BMJ 2007;334:786-786.
ABSTRACT | FULL TEXT  

Intensive Intraoperative Insulin Therapy versus Conventional Glucose Management during Cardiac Surgery: A Randomized Trial
Gandhi et al.
ANN INTERN MED 2007;146:233-243.
ABSTRACT | FULL TEXT  

Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials
Skali et al.
Circulation 2006;114:2298-2303.
ABSTRACT | FULL TEXT  

Keeping Apples and Oranges Separate: Reassessing Clinical Trials That Use Composite End Points as Their Primary Outcome
Chan et al.
J Am Coll Cardiol 2006;48:850-850.
FULL TEXT  

High-dose statins and the IDEAL study.
Chan et al.
JAMA 2006;295:2477-2477.
FULL TEXT  

Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.
Briel et al.
JAMA 2006;295:2046-2056.
ABSTRACT | FULL TEXT  

Therapeutic hypothermia following perinatal asphyxia.
Edwards and Azzopardi
Arch. Dis. Child. Fetal Neonatal Ed. 2006;91:F127-F131.
ABSTRACT | FULL TEXT  

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial
Jespersen et al.
BMJ 2006;332:22-27.
ABSTRACT | FULL TEXT  

Methodological issues in trials assessing primary prophylaxis of venous thrombo-embolism
Thabut et al.
Eur Heart J 2006;27:227-236.
ABSTRACT | FULL TEXT  

How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
Freemantle
BMJ 2005;331:836-838.
FULL TEXT  

Lithium in the Prevention of Suicidal Behavior and All-Cause Mortality in Patients With Mood Disorders: A Systematic Review of Randomized Trials
Cipriani et al.
Am. J. Psychiatry 2005;162:1805-1819.
ABSTRACT | FULL TEXT  

DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction: DECOPI or NOT DECOPI: more smoke on the horizon
Achrafi
Eur Heart J 2005;26:1566-1567.
FULL TEXT  

Validity of composite end points in clinical trials
Montori et al.
BMJ 2005;330:594-596.
FULL TEXT  

Antibiotics for the Secondary Prevention of Ischemic Heart Disease: A Meta-analysis of Randomized Controlled Trials
Wells et al.
Arch Intern Med 2004;164:2156-2161.
ABSTRACT | FULL TEXT  

The case for statins: has it really been made?
Thompson and Temple
JRSM 2004;97:461-464.
FULL TEXT  

New answers raise new questions in pulmonary arterial hypertension
Kawut and Palevsky
Eur Respir J 2004;23:799-801.
FULL TEXT  

Composite confusion
Massel
J Am Coll Cardiol 2004;43:1926-1927.
FULL TEXT  

Effects of Estrogen Plus Progestin on Risk of Dementia--Reply
Shumaker et al.
JAMA 2003;290:1707-1708.
FULL TEXT  

Use of Composite End Points to Measure Clinical Events
van Leth and Lange
JAMA 2003;290:1456-1457.
FULL TEXT  

Clinical Trials--Multiple Treatments, Multiple End Points, and Multiple Lessons
Lauer and Topol
JAMA 2003;289:2575-2577.
FULL TEXT